Science by Consensus: Why the NIH Grant Review System Must Be Changed

One of the foremost concerns of biomedical scientists in the United States is the difficulty in obtaining grant funding from the National Institutes of Health. The NIH grant review system has now become like the weather: Everybody talks about it, but nobody seems to be able to do anything about it. A disturbing example of the shortcomings of NIH review panels was provided by John McGowan, the director of extramural research at the National Institute of Allergy and Infectious Diseases. He courag

Written byNejat nes
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

One of the foremost concerns of biomedical scientists in the United States is the difficulty in obtaining grant funding from the National Institutes of Health. The NIH grant review system has now become like the weather: Everybody talks about it, but nobody seems to be able to do anything about it. A disturbing example of the shortcomings of NIH review panels was provided by John McGowan, the director of extramural research at the National Institute of Allergy and Infectious Diseases. He courageously revealed that several proposals to investigate HIV infection of macrophages had been rejected by a review panel ("study section") with the pretext that "the literature does not support the hypothesis that HIV can grow in macrophages."1

It is now well known that macrophage-tropic strains of HIV infect macrophages and are thought to initiate infection in humans. It is clear that our understanding of HIV pathogenesis would have been ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies